Radiogenomic evaluation of tumour response to targeted agents
Radiogenomics should be an integral part of drug development, according to Dr Korn who talks to ecancer about this evolving field at TAT 2015.
Dr. Ron Korn of Imaging Endpoints to Present at Pharmatech’s Biomarker Panel
April 2014 - Ron Korn, MD, PhD, of Imaging Endpoints will be a featured presenter at Pharmatech's Biomarker Panel entitled "Development of Oncology Clinical Trials in the time of Precision, Personalized Medicine" occurring on May 15, 2014 at the Marriott… Read More
ALK Molecular Phenotype in Non-Small Cell Lung Cancer: CT Radiogenomic Characterization
Purpose: To present a radiogenomic computed tomographic (CT) characterization of anaplastic lymphoma kinase (ALK) rearranged non–small cell lung cancer (NSCLC) (ALK+). Materials and Methods: In this HIPAA-compliant institutional review board–approved retrospective study, CT studies, ALK status, and clinical-pathologic data in… Read More
Noninvasive Image Texture Analysis Differentiates K-ras Mutation from Pan-Wildtype NSCLC and Is Prognostic
Abstract Background: Non-invasive characterization of a tumor’s molecular features could enhance treatment management. Quantitative computed tomography (CT) based texture analysis (QTA) has been used to derive tumor heterogeneity information, and the appearance of the tumors has been shown to relate… Read More
AG Mednet and Imaging Endpoints Partner to Set Clinical Trial Benchmark for Image Data Quality and Compliance
Boston, MA – May 7, 2014 – AG Mednet and the board-certified, fellowship-trained radiologists at Imaging Endpoints believe strongly that every clinical trial data point counts, from pre-clinical through FDA submission. To support its guarantee of accuracy, compliance, real-time reads… Read More
Imaging Endpoints presents Poster at AACR 2014 in conjunction with Merrimack Pharmaceuticals
April 2014 - Imaging Endpoints presents Poster at AACR 2014 in conjunction with Merrimack Pharmaceuticals and Virginia C. Piper Cancer Center. The Poster, entitled "Pilot study in patients with advanced solid tumors to evaluate feasibility of ferumoxytol (FMX) as a… Read More
Imaging Endpoints presents Poster at AACR 2014 in conjunction with RadioRx
April 2014 - Imaging Endpoints presents Poster at AACR 2014 in conjunction with RadioRx, Inc. and the University Of Arizona College Of Medicine. The Poster, entitled "RRx-001 Oxidation of Redox Sensitive Protein Thiols in Tumors Measured by Gd-LC7-SH Enhanced MRI… Read More
Imaging Endpoints presents Poster at AACR 2014 in conjunction with the University Of Arizona College Of Medicine
April 2014 - Imaging Endpoints presents Poster at AACR 2014 in conjunction with the University Of Arizona College Of Medicine, The Translational Genomics Research Institute (TGen) and The Virginia G. Piper Cancer Center. The Poster, entitled "Quantitative Textural Analysis (QTA)… Read More
Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study
This study was designed to evaluate whether subjects with amyloid beta (Aβ) pathology, detected using florbetapir positron emission tomorgraphy (PET), demonstrated greater cognitive decline than subjects without Aβ pathology. Sixty-nine cognitively normal (CN) controls, 52 with recently diagnosed mild cognitive… Read More
Non-invasive advanced image analysis could lead to better patient care
TGen, Scottsdale Healthcare, and Cancer Centers of America are leading new research studies for patients suffering with lung cancer.
